linjc16/ctgov huggingface dataset:
Value of Routine Hysteroscopy Prior to IVF/ICSI Cycles

Study Overview
=================
Brief Summary
-----------------
In the current study the investigators hypothesize that Routine Hysteroscopy prior to IVF/ICSI cycle increases the clinical pregnancy rate.

Detailed Description
-----------------
A randomized controlled study involving 300 patients with recurrent implantation failure

Conditions
-----------------
Infertility

Intervention / Treatment
-----------------
* Device: Hysteroscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient's age ranged from 20-40 years. Normal appearance of the uterine cavity on hysterosalpingography. Patients prepared for IVF/ICSI cycle. Exclusion Criteria: Patients who have any contraindications for hysteroscopy. (Menstruation, pregnancy, severe vaginitis or cervicitis, endometrial infection and history of Pelvic Inflammatory Diseases). Patients with uterine cavity pathology previously known to the examiner. Patients with previous uterine surgery such as myomectomy. Patients with abnormal HSG.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Routine Invistigations<br>ICSI with long luteal phase protocol | |
| Experimental: Hysteroscopy<br>hysteroscopy will be done prior to the ICSI cycle | Device: Hysteroscopy<br>* hysteroscopy and endometrial injury prior to the IVF/ICSI cycle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| • Clinical pregnancy rate. |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| • Live Birth Rate |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hysteroscopy - recurrent implantation failure
Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the safety and efficacy of the composite Nail - the Quantum interlocking intramedullary nailing system in the reduction of humeral fractures.

Detailed Description
-----------------
The study will include 20 patients who have an acute mid shaft diaphyseal humeral fracture due to injury. The patients will undergo lateral and AP X- ray evaluation of the fracture. Following General anesthesia, closed reduction of the fracture will be performed. It will be followed by nail insertion, percutaneously, according to standard surgical techniques, with the help of the insertion handle and without preliminary reaming. Following insertion the nail will be locked both distally and proximally using interlocking screws. The nail and screws insertion will be monitored by fluoroscopy. Patients will remain under follow up for 6 months following the procedure. In the follow up sessions the fracture will be evaluated by fluoroscopy or X-ray for correct bone alignment, callus formation, and fracture union.

Official Title
-----------------
Composite Nailing System for the Intramedullary Fixation of Humerus Fractures Without Intramedullary Reaming

Conditions
-----------------
Humeral Fractures, Pathological Fractures

Intervention / Treatment
-----------------
* Device: Quantum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above 18 years old. Mid shaft diaphyseal fracture Acute fracture Exclusion Criteria: Patients with metabolic or hormonal diseases that could affect bone healing such as diabetes. Ongoing infection in fracture site.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: single arm<br>In this single arm study, the Quantum nailing system will be used in all patients. | Device: Quantum<br>* Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bone union and callus formation,bone alignment, nail and screws resistance over time |  | up to 6 months |
Integration of Palliative Care in an Oncology and Hematology Unit

Study Overview
=================
Brief Summary
-----------------
The main goal of this study is to assess retrospectively the integration of Palliative Care in an oncology and hematology unit. The investigators will study the last six month of life on advanced cancer patients and retrieve data from their medical file to obtain criterias of quality of care and integration of palliative care in this population. Those criterias have been used before in other setting (Earle Criterias, ESMO Recommendations) and The investigators will compare our data to existing publications. They also hope to see if it is retrospectively possible to assess the probability of death using the Pronopall score. This will help them asses if aggressive end of life care could have been avoided using the Pronopall Score

Official Title
-----------------
Integration of Palliative Care in an Oncology and Hematology Unit : a Retrospective Monocentric Study

Conditions
-----------------
Advanced Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged over 18 years old Patient who has been followed in the oncohematology Unit of the University Hospital of Strasbourg for a solid tumor or haematological cancer Died within the 1rst of January 2017 and the 31st of December 2018 The patient has not expressed an opposition to the use of his medical data during his lifetime. Exclusion Criteria: Patient receiving allogeneic stem cell transplant Patient expressed during his lifetime an opposition regarding the use of his medical data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective study of palliative care in oncohematology department |  | The period from January 1st, 2017 to December 31, 2018 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced Cancer, End of Life, Agressiveness of Care, Palliative Care integration
Early Mobilisation Following Discectomy

Study Overview
=================
Brief Summary
-----------------
After lumbar discectomy 1st postoperative day high intensity exercise training reduced hospital stay, pain and sick leave without side effects in the two year follow-up period.

Detailed Description
-----------------
Postoperative pain is a major cause of delayed convalescence after discectomy. Different analgesic treatments with the use of local analgesics and steroid can reduce the immediate postoperative pain and convalescence after surgery. In orthopaedic and abdominal surgery accelerated stay programs with early mobilisation have reduced pain in the early postoperative periode. The late convalescence after discectomy for herniated disc disease can be reduced with the use of epidural steroids.

Official Title
-----------------
Early Mobilisation Following Discectomy

Conditions
-----------------
Reduced Hospital Stay Without Complication

Intervention / Treatment
-----------------
* Behavioral: Care program
* Behavioral: Care program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with primary lumbar herniated disc disease who have received and performed a standardized conservative treatment program with intensive exercises. Oral and written acceptance. Age 18 and above. Exclusion Criteria: Patients with central or lateral spinal stenosis due to spondylosis or disc degeneration who needed bilateral decompression, laminectomy or fusion. Patients with cauda equina syndrome who needed acute operative treatment.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Control group<br>Median age 45 years, 18-63. | Behavioral: Care program<br>* Care program with multimodal pain treatment including epidural steroid<br>* Other names: No other names.;|
| Intervention group<br>Median age 46 years, 18-62. | Behavioral: Care program<br>* Care program with multimodal pain treatment including epidural steroid.<br>* Other names: No other names.;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Discectomy, 1st postoperative day, Intensive exercise training, Randomized controlled trial
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Study Overview
=================
Brief Summary
-----------------
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment.

Detailed Description
-----------------
To evaluate the long-term outcome of active choroidal neovascularization (CNV) in punctate inner choroidopathy (PIC) or multifocal choroiditis (MFC) after anti-vascular endothelial factor treatment. The age, sex, best corrected visual acuity (BCVA) in Snellen chart, and refractive status for each patient were recorded. All patients had thorough clinical examinations, including slit lamp biomicroscopy, indirect ophthalmoloscopy, and spectral domain optical coherence tomography during each visit. Fundus photography, fluorescein angiography, and indocyanine angiography were performed on all patients. OCT angiography was performed.

Official Title
-----------------
Long-term Outcome of Punctate Inner Choroidopathy or Multifocal Choroiditis With Active Choroidal Neovascularization Managed With Anti-vascular Endothelial Growth Factor

Conditions
-----------------
Choroidal Neovascularization, Punctate Inner Choroidopathy

Intervention / Treatment
-----------------
* Drug: Bevacizumab Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization. Follow up over 4 years. Exclusion Criteria: Patients were not punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization Patients were punctate inner choroidopathy or multifocal choroiditis with active choroidal neovascularization but loss follow over 1 year.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Bevacizumab Injection|Anti-vascular endothelial growth factor (VEGF)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wilcoxon Signed-Rank test | A statistical comparison of average of two dependent samples | Baseline,48 month. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity | visual acuity in logMAR | Baseline,48 month. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
punctate inner choroidopathy, multifocal choroidits, choroidal neovascularization, anti-VEGF, long-term outcome
Failure Time Methods for Family Disease Studies

Study Overview
=================
Brief Summary
-----------------
To develop statistical methodologies to study genetic and environmental factors in cardiovascular disease, using age at onset data from population-based family studies of disease incidence.

Detailed Description
-----------------
BACKGROUND: In the study of chronic diseases, both environmental and genetic factors can be influential. In highly common diseases, such as coronary heart disease, genetic effects may be more influential in determining the age of onset of the disease than in determining whether or not one gets the disease. When sufficient information is available, family studies can help localize possible disease genes on the human chromosome through genetic linkage analysis, and familial aggregation of disease can help separate the effects of inheritance, environment and lifestyle on the risk of disease. DESIGN NARRATIVE: The study developed: (1) a general strategy for evaluating the fit of parametric dependence models for familial clustering of ages at disease-onset; (2) a computationally simple method for genetic linkage analysis of age at onset data; (3) application and illustration of recently developed additive frailty models for complex familial dependence structures. Method (1) was applied to a family study of cardiovascular disease and a twin study of appendectomy. Method (2) was applied to ongoing genetic studies conducted at the University of California at San Francisco. Method (3) was applied to a family study of coronary heart disease in Western Australia. Well-documented, user-friendly programs were developed and made publicly available. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Heart Diseases, Cardiovascular Diseases, Coronary Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Measuring HIV Quality of Care

Study Overview
=================
Brief Summary
-----------------
The VA is the largest single provider of HIV care in the United States. The late 1990's have seen a revolution in the quality standards for this disease with the onset of Highly Active Antiretroviral Therapy (HAART) and other developments.

Detailed Description
-----------------
Background: The VA is the largest single provider of HIV care in the United States. The late 1990's have seen a revolution in the quality standards for this disease with the onset of Highly Active Antiretroviral Therapy (HAART) and other developments. Objectives: Our purpose in this project is to develop a method for assessing quality in two important areas of HIV care - antiretroviral medications and opportunistic infection screening and prophylaxis - and explore the determinants of high quality care in order to suggest quality improvement strategies. Methods: The analysis has four parts. First, it will describe the level of adherence to the indicators in VA HIV patients nationwide and compare VA HIV patients to national benchmarks. Second, it will analyze facility and patient level predictors of adherence to indicators of quality of care and compare them with the predictors in the non VA population using staged logistic regressions. Third, it will seek to validate certain indicators (e.g. HAART therapy) against clinical outcomes like hospitalization and immune status. We will also model the clinical price that the VA pays in suboptimal clinical outcomes as a result of current performance levels. Fourth, we will compare the performance of the facilities after one year of an intensive targeted indicator-specific feedback group versus those receiving aggregate data only. Status: Data analysis.

Official Title
-----------------
Measuring HIV Quality of Care

Conditions
-----------------
HIV Positive, Facility Level Care, Clinical Reminder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Facilities with HIV clinics Exclusion Criteria:
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Clinical Evaluation of a Paediatric Sleep Diagnosis Technology

Study Overview
=================
Brief Summary
-----------------
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population. The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography.

Detailed Description
-----------------
The objective of this project is to gather research data and subsequently evaluate algorithms to demonstrate clinical efficacy of a novel sleep apnoea detection system in the paediatric population. The Study will involve patients who will have been referred for diagnosis of sleep apnoea, and the ultimate aim will be to compare the output of a novel apnoea detection system against in -clinic polysomnography. Patients who are referred to the clinic will spend one night's sleep in the clinic. They will wear a polysomnography system (current goldstandard) and the novel device. At the end of the trial, we will compare the diagnosis results from both systems.

Official Title
-----------------
Clinical Evaluation of a Paediatric Sleep Diagnosis Technology

Conditions
-----------------
Sleep Apnea

Intervention / Treatment
-----------------
* Device: Novel wearable paediatric device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children older than one year old Children who have been referred to a sleep clinic due to suspicion of sleep apnoea. Exclusion Criteria: Patients whose parents/legal guardians/carers are not fluent in English, or who have special communication needs. Known allergy to the adhesive dressing. Patients with physical or mental impairments who would be too distressed with additional sensors on themselves. Patients with not enough space on the neck area to fit the sensor. Clinical problem in the area in which the device will be attached, eg skin condition

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| test group<br>Test group will wear PSG | Device: Novel wearable paediatric device<br>* The patient will wear the novel wearable paediatric device at the same time as polysmnography<br>|
| Novel wearable device<br>THis group will wear the novel device | Device: Novel wearable paediatric device<br>* The patient will wear the novel wearable paediatric device at the same time as polysmnography<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Specificity and sensitivity of novel device | specificity and sensitivity of the output of the novel wearable device against polysomnography | 6 months |
Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Randomized Clinical Trial to evaluate which is the best infusion system of heparin solution for Keeping the mean invasive blood pressure whether the continuous system and the intermittent one.

Official Title
-----------------
Continuous or Intermittent for Keeping Arterial Catheter in Children: A Randomized Clinical Trial

Conditions
-----------------
Blood Pressure

Intervention / Treatment
-----------------
* Other: Infusion Intermittent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients in post-operative in congenital heart disease under 15 kg Exclusion Criteria: no consent of parents or responses

Ages Eligible for Study
-----------------
Maximum Age: 93 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Continuous Infusion<br> | |
| Intermittent Infusion<br> | |
| Infusion Continuous<br> | Other: Infusion Intermittent<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| blooding |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
blood pressure, pediatric, nursing, maintenance arterial catheter